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Background: Diabetes mellitus type 1 is an autoimmune disorder caused by lymphocytic infiltration and beta
cells destruction. Curcumin has been identified as a potent inducer of heme-oxygenase-1 (HO-1), a redoxsensitive
inducible protein that provides protection against various forms of stress. A novel water soluble curcumin derivative
(NCD) has been developed to overcome low in vivo bioavailability of curcumin. The aim of the present work is
to evaluate the anti diabetic effects of the “NCD” and its effects on diabetes-induced ROS generation and lipid
peroxidation in experimental type- 1 diabetes mellitus. We also examine whether the up regulation of HO-1
accompanied by increased HO activity mediates these antidiabetic and anti oxidant actions.
Materials and methods: Rats were divided into control group, control group receiving curcumin derivative,
diabetic group, diabetic group receiving curcumin derivative and diabetic group receiving curcumin derivative and
HO inhibitor ZnPP. Type-1 diabetes was induced by intraperitoneal injection of streptozotocin. Curcumin derivative
was given orally for 45 days. At the planned sacrification time (after 45 days), fasting blood samples were
withdrawn for estimation of plasma glucose, plasma insulin and lipid profile . Animals were sacrificed; pancreas,
aorta and liver were excised for the heme oxygenase - 1 expression, activity and malondialdehyde estimation.
Results: NCD supplementation to diabetic rats significantly lowered the plasma glucose by 27.5% and increased
plasma insulin by 66.67%. On the other hand, the mean plasma glucose level in the control group showed no
significant difference compared to the control group receiving the oral NCD whereas, NCD supplementation to
the control rats significantly increased the plasma insulin by 47.13% compared to the control. NCD decreased total
cholesterol, triglycerides, LDL cholesterol and increased HDL cholesterol levels. Also, it decreased lipid peroxides
(malondialdehyde) in the pancreas, aorta and liver.
Conclusion: The (NCD) by its small dose possesses antidiabetic actions and that heme oxygenase induction seems
to play an important role in its anti-diabetic effects. NCD also improves the lipid profile and oxidative status directly,
proved by decreasing lipid peroxides (malondialdehyde) in pancreas, liver & aorta. The new water soluble curcumin
derivative still retains the essential potencies of natural curcumin.
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Diabetes is the most common endocrine disorder and it
was reported that by the year 2010 more than 200 mil-
lion people worldwide will have diabetes mellitus (DM)
and 300 million will subsequently have the disease by
2025[1]. There is increasing evidence that complications
related to DM are associated with increased oxidative
stress induced by generation of free radicals [2]. These
reactive oxygen species play an important role in the
pathogenesis and development of complications of dia-
betes. The antioxidant treatment which suppresses apop-
tosis of β-cells was shown to preserve β-cell function in
diabetic mice [3].
Exposure of endothelial cells to elevated blood glucose
levels leads to the generation of excess reactive oxygen
species (ROS) in the cells [4]. Hyperglycemia-mediated
local formation of ROS is considered to be a major con-
tributing factor to endothelial dysfunction, including
abnormalities in cell cycling [5] and delayed replication
[6]; these abnormalities can be reversed by antioxidant
agents[7] or by increased expression of antioxidant
enzymes[8]. Du et al. [9] demonstrated that hypergly-
cemia stimulates the induction of apoptosis in endothe-
lial cells by a mechanism that involves the generation
of ROS and superoxide anion (O2
_.). A reduction in
antioxidant reserves has been related to endothelial cell
dysfunction in diabetes, even in patients with well-
controlled glucose levels [10]. In a recent study [4], it
was demonstrated that increased expression of heme-
oxygenase −1(HO-1) attenuates glucose-mediated cell
growth arrest and reduces apoptosis in human microves-
sel endothelial cells.
Curcumin (1, 7 bis (4 hydroxy-3 methoxy phenol)-1, 6
heptadiene-3, 5 dione) is a yellow phenolic compound
present in tumeric (Curcumalonga) a widely used
spice in Indian cuisine. Curcumin has a number of bio-
logical applications along with a significant antioxidant
activity both invivo and invitro [11]. Studies have sug-
gested a strong intrinsic activity and, hence, efficacy of
curcumin as a therapeutic agent for various ailments.
However, studies over the past three decades related
to absorption, distribution, metabolism and excretion
of curcumin have revealed poor absorption and rapid
metabolism of curcumin that severely curtails its bio-
availability [12].
Heme oxygenase (HO) catalyzes the rate-limiting step
in oxidative degradation of heme to biliverdin, produ-
cing equimolar quantities of carbon monoxide (CO),
iron. Biliverdin is then converted to bilirubin by bilirubin
reductase. In addition, HO-1 has emerged as an import-
ant mediator of cellular defence against wide-ranging
tissue injuries. The antioxidant and antiapoptotic actions
of HO-1 have been also attributed to the by-products
of heme degradation namely, CO and biliverdin [13].The role of HO system in insulin release and glu-
cose metabolism is becoming increasingly clear [14,15].
HO-mediated stimulation of insulin release has been
reported in different rat strains [14]. Heme oxygenase cat-
alyzes the carbon monoxide (CO) production, which has
important biological effects, including antioxidant, anti-
inflammatory, and cytoprotective functions [16]. Studies
suggest a central role of CO in glucose metabolism. In
the human body, CO is formed at a rate of 16.4 mol/h
[17]. Normally, the islets of Langerhans produce CO and
nitric oxide (NO) to regulate insulin release. While NO
negatively modulates glucose-stimulated insulin release,
CO stimulates insulin secretion, moreover, glucose stimu-
lates pancreatic β-cells to produce CO, which in turn trig-
gers insulin release [18].
The transient up-regulation of HO-1 that normally
accompanies many pathophysiological conditions may
represent the first line of defense against tissue injury
to counteract the adverse changes that would destabilize
the homeostatic in physiological milieu. This could be
achieved by pharmacological agents capable of inducing
HO-1 like cobalt protoporphyrin or some herbal medi-
cines. Curcumin has been reported to induce HO-1
expression [19]. Increased HO activity is an important
component in curcumin-mediated cytoprotection against
oxidative stress [20].
Because of the poor bioavailability of pure curcumin, a
new water soluble curcumin derivative (Patent pending
PCT/EG2010/000008) was used in this study.
The aim of the present work is to evaluate the anti
diabetic effects of the “NCD” and its effects on diabetes-
induced ROS generation and lipid peroxidation in
experimental type- 1 diabetes mellitus. We also examine
whether the up regulation of HO-1 accompanied by
increased HO activity mediates these antidiabetic and
anti oxidant actions.Materials and methods
This work was performed at the Unit of Biochemistry
and Molecular Biology at the Medical Biochemistry
Department, Faculty of Medicine, Cairo University, Egypt.
Curcumin protein conjugate was presented free of charge
to the participating researchers as a personal non-profit
scientific donation to help advancement of cooperation
in national medical research. The novel derivative, (PCT/
EG2010/000008, Published Patent Pending, WO 2011/
100984) with 3.0% curcumin content is registered as
international patent protected by the rights of “The
Patent Cooperation Treaty” and are the personal property
of its inventors.
The novel curcumin derivative “NCD” developed
through covalent modification of the curcumin molecule
on sites remote from its natural functional groups.
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The study was carried on fifty rats, of an average weight
150–200 gm obtained from an inbred colony (Curl: HEL
1) at the Kasr Al-Aini animal experimental unit, Faculty
of Medicine, Cairo University. Rats were bred and main-
tained in an air-conditioned animal house with specific
pathogen-free conditions, and were subjected to a 12:12-
h daylight/darkness and allowed unlimited access to
chow and water. All the ethical protocols for animal
treatment were followed and supervised by the animal
facilities, Faculty of Medicine, Cairo University. All ani-
mal experiments received approval from the Institutional
Animal Care Committee. The rats were divided into the
following groups:
1. Twenty control rats divided into:a) Ten Control rats were injected with citrate buffer
alone to serve as a normal control group.
b) Ten rats representing the control group that
receive novel water soluble curcumin derivative
(NCD) (10 mg/kg body weight, was dissolved
in distilled water) daily by oral gavage for
45 days.
2. Thirty diabetic rats divided into:
 Ten rats representing the streptozotocin-induced
diabetic rats. (65 mg/kg of STZ dissolved in 0.1 M
sodium citrate buffer, pH 4.5, intraperitoneally
once)
 Ten diabetic rats that receive NCD (10 mg/kg
body weight was dissolved in distilled water) daily
by oral gavage for 45 days.
 Ten diabetic rats that receive NCD (10 mg/kg
body weight was dissolved in distilled water)
daily by oral gavage and HO inhibitor Zinc
protoporphyrin (10micromol/kg, ZnPP were
dissolved in sodium hydroxide 0.1 N and sodium
chloride 0.9% and pH adjusted to pH 7.4)
intraperitoneally once a week for 6 weeks starting
from the day after development of diabetes.
Collection of blood and tissue samples
At the planned time of sacrifaction (after 45 days), fast-
ing blood samples (after 12–14 hrs) were withdrawn
from the retro-orbital vein and processed immediately
into two tubes; one containing fluoride for immediate
estimation of fasting plasma glucose and the second tube
containing EDTA for separation of plasma. The tubes
were centrifuged and the plasma was separated and
stored at – 20°C. This was followed by sacrifaction of
the animals by cervical dislocation. The pancreas, aorta
and liver were excised and stored at −80°C.Estimation of glucose and insulin
Plasma glucose was estimated by the glucose oxidase
method [21] and plasma insulin was estimated [22] by a
commercially available Enzyme-linked immunosorbent
assay (ELISA) kit supplied by DRG Diagnostics (GmbH,
Germany).
Estimation of lipid profile
The lipid profile was estimated by available kits supplied
by Diamond Diagnostics, Egypt [23–25].
Estimation of lipid peroxides (malondialdehyde) in tissues
Pancreatic, aortic and liver tissue MDA was assayed by a
commercial kit supplied by Biodiagnostic, Egypt [26].
HO activity assay
Pancreatic, aortic and liver tissues were homogenized
with 3 volume homogenization buffer. The homoge-
nate was centrifuged at 3000 rpm for 4 min and then
at 14,000 rpm for 5 min at 4°C to produce the mito-
chondrial pellet. The supernatant was withdrawn. The
protein content was determined by the method of Lowry
et al. [27]. The activity of HO in the supernatant
was determined as previously described by Abraham
el al. [28].
RNA extraction
Total RNA was extracted from pancreatic, aortic and
liver tissues by using SV Total RNA Isolation System
supplied by Promega (Promega, Madison, WI, USA)
according to the manufacturer’s protocol [29]. The yield
of total RNA was determined spectrophotometrically at
260 nm, where 1 absorbance unit (A260) equals 40 μg of
single stranded RNA/mL.
Reverse transcription-polymerase chain reaction
for HO-1 expression
The extracted RNA was reversed transcribed into cDNA
using Access RT-PCR System kit supplied by Promega
(Promega, Madison, WI, USA) following the manufac-
turer's instructions [30]. The cDNA products were amp-
lified by PCR in a total volume of 50 μl containing 5 U
Taq DNA polymerase (Promega) and 50 pmol each of
the upstream and downstream primers. After predena-
turation at 94°C for 2 min, 40 cycles were allowed to run
for 30 s at 94°C, followed by 1 min at 60°C and 2 min at
68°C, and a final extension at 68°C for 7 min. Reverse
transcription-polymerase chain reaction (RT-PCR) for β-
actin (housekeeping gene) was performed to confirm the
integrity of extracted RNA.
The primers for HO-1 (GenBank accession number
J-02722) were Forward primer:50- CTGCTAGCCTGGTT-
CAAGATA-30,and Reverse primer: 50- CATCTCCTTC-
CATTCCAGAG-30. Primers for β-actin (UniSTS: 270185,
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GGCATGGAGTCCT-30 and Reverse primer: 50- GGAG-
CAATGATCTTGATCTTC-30.
The predicted sizes of the amplified HO-1 and β-actin
DNA products were 316 bps and 202 bps, respectively.
Amplified products (5 μl) were loaded onto 1.5% agarose
gels previously stained with 0.5 μg/ml ethidium bromide,
electrophoresed at 100 V for 30 min and then visualized
by UV transilluminator. The PCR products were semi-
quantitated using the gel documentation system (Bio Doc
Analyze) supplied by Biometra (Go¨ttingen, Germany).
Statistical analysis
Unpaired Student's t-test was used for testing statistical
significance of difference between every 2 groups using
the PC software “Statistica version 8.0” of Statsoft Inc.,
USA. Data were presented as mean percent change for
relevant groups. The differences between groups were
considered to be significant at p< 0.05.
Results
This study was conducted on 50 female (Curl: HEL 1)
rats. At the time of scarification (after 45 days), 46 rats
were remaining.
Blood glucose and insulin levels
There was a significant increase (p < 0.001) in the mean
plasma glucose level in the diabetic group (349.6 ±
77.99 mg/dL) compared to the control group (83.7 ±
6.56 mg/dL). On the other hand the mean plasma glu-
cose level in the control group (83.7 ± 6.56 mg/dL)
showed no significant difference (p > 0.05) compared
to the control group receiving the oral NCD (81.9 ±
5.78 mg/dL). Oral NCD supplementation to diabetic rats
resulted in a significant (27.5%) decrease (p < 0.05) in the
mean plasma glucose level (253.5 ± 48.51 mg/dL) com-
pared to the diabetic group (349.6 ± 77.99 mg/dL). There
was a significant increase (p < 0.05) in the mean plasma
glucose level in the diabetic group receiving the oral
NCD combined with HO inhibitor ZnPP (315.9 ±
58.54 mg/dL) compared to the diabetic group receiving
the oral NCD (253.5 ± 48.51 mg/dL).
A significant decrease (p < 0.001) in the mean plasma
insulin level in the diabetic group (0.39 ± 0.09 μg/L)
compared to control group (0.87 ± 0.24 μg/L) was
detected. In addition, there was a significant increase
(47.1%) (p < 0.05) in the mean plasma insulin level in the
control group receiving the oral NCD (1.28 ± 0.3 μg/L)
compared to the control group (0.87 ± 0.24 μg/L). Oral
NCD supplementation to diabetic rats resulted in a sig-
nificant increase (p < 0.001) in the mean plasma insulin
level (0.65 ± 0.09 μg/L) compared to the diabetic group
(0.39 ± 0.09 μg/L). Whereas, supplementation of ZnPP to
diabetic rats receiving the oral water soluble curcuminshowed a significant decrease (p < 0.05) in plasma insulin
levels(0.52 ± 0.12 μg/L) compared to the diabetic group
receiving the oral NCD (0.65 ± 0.09 μg/L) (Table 1).
Malondialdehyde levels in different tissues
There was a significant increase (< 0.05) in MDA in pan-
creas (65.3%) (93.7 ± 12.55 nmol/g tissue), liver (55.3%)
(523.7 ± 58.35 nmol/g tissue) and aorta (93.6%) (57.3 ±
7.74 nmol/g tissue) of diabetic rats compared to the cor-
responding control groups (56.7 ± 6.73, 337.3 ± 44.69
and 29.6 ± 5.6 nmol/g tissue), respectively.
Supplementation of the water soluble curcumin deriva-
tive to diabetic rats significantly decreased (< 0.05) the
levels of MDA in these tissues (pancreas (28.9%); 66.62 ±
5.5 nmol/g tissue), (liver (29.8%; 367.7 ± 37.3 nmol/g
tissue) and (aorta (19.7%); 46±4.37 nmol/g tissue).
The mean MDA level in the pancreas (56.7 ±
6.73 nmol/g tissue), liver (337.3 ± 44.69 nmol/g tissue)
and aorta (29.6 ± 5.6 nmol/g tissue) of the control group
showed no significant difference (p>0.05) compared to
the control group receiving the oral NCD (53.2 ± 8.01,
331.3 ± 33.12 and 28 ± 4.16 nmol/g tissue), respectively.
Although the MDA level was increased in the pancreas
(70.8 ± 8.06 nmol/g tissue), liver (416.1 ± 64.2 nmol/g tis-
sue) and aorta (51.9 ± 4.17 nmol/g tissue) of diabetic rats
receiving the curcumin derivative and ZnPP compared
to the diabetic rats receiving the NCD only, the increase
was found to be statistically significant (p < 0.05) only
in the aorta (46 ± 4.37 nmol/g tissue) (Figure 1).
Heme –oxygenase −1 expression in different tissues
There was a significant increase (p < 0.001) in the mean
HO-1 expression level in pancreas (990 ± 74.3 μg/mL)
and liver (1088.3 ± 168.7 μg/mL) of diabetic rats com-
pared to the corresponding control groups (492.7 ±
80.13 μg/mL and 560 ± 74.7 μg/mL), respectively. On the
contrary, the HO-1 expression in the aorta (290.6 ±
40.7 μg/mL) of diabetic rats showed a significant
decrease (p < 0.001) compared to the control group
(491.4 ± 68.6 μg/mL).
Curcumin supplementation to the control rats signifi-
cantly increased (p < 0.001) the HO-1 expression in the
pancreas (864.3 ± 62 μg/mL), liver (852.7 ± 83.43 μg/mL)
and aorta (835.9 ± 64.7 μg/mL) compared to the corre-
sponding control groups (492.7 ± 80.1, 560 ± 74.7 and
491.4 ± 68.6 μg/mL).
In addition, curcumin supplementation to the diabetic
rats significantly increased the HO-1 expression in
the pancreas (1300.5 ± 166.2 μg/mL), liver (1707.7 ±
212.3 μg/mL) and aorta (758 ± 73.23 μg/mL) compared
to the corresponding control groups (492.7± 80.13, 560 ±
74.7 and 491.4 ± 68.6 μg/mL), respectively.
Also, curcumin supplementation to the diabetic rats
significantly increased the HO-1 expression in the pancreas













Control (n = 10) 83.7 ± 6.56 # 0.87 ± 0.24 84.4 ± 6.85# 85.5 ± 7.56# 25.4 ± 7.82# 41.8 ± 4.18#
Control +NCD (n= 10) 81.9 ± 5.78 # 1.28 ± 0.3 83 ± 11.01# 83.6 ± 8.01# 25.5 ± 7.54# 40.7 ± 3.68#
Diabetic (n = 8) 349.6 ± 77.99* 0.39 ± 0.09 140.1 ± 30.86* 181.6 ± 25.19* 76.4 ± 26.85* 27.25 ± 4.49*
Diabetic +NCD (n =8) 253.5 ± 48.51*# 0.65 ± 0.09 91.88 ± 9.61# 133.5 ± 14.74*# 25.5 ± 6.76# 38.6 ± 4.09#
Diabetic +NCD+ZnPP (n =10) 315.9 ± 58.54* 0.52 ± 0.12 93.5 ± 12.51# 128.2 ± 12.09*# 27.4 ± 11.36# 40.2 ± 4.97#
Results are presented as mean ± SD.
*Values differ significantly from control (P < 0.05).
#Values differ significantly from diabetic p < 0.05.
NCD=novel curcumin derivative.
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aorta (758± 73.23 μg/mL) compared to the corresponding
diabetic groups (990±74.3, 1088.3 ± 168.7 and 290.6 ±
40.7 μg/mL), respectively (Figures 2, 3a and 3b).
There was a significant decrease (p < 0.05) in the mean
HO-1 gene expression in the diabetic group receiving the
oral NCD combined with HO inhibitor ZnPP in pan-
creas (619.6 ± 49.4 μg/mL), liver (1208.4 ± 139.36 μg/mL)
and aorta (446.8 ± 56.1 μg/mL) compared to the corre-
sponding diabetic group receiving the oral NCD (1300.5 ±
166.2, 1707.7± 212.3and 758±73.23 μg/mL), respectively
(Figures 2 and 4).
Heme –oxygenase activity in different tissues
There was a significant increase (p < 0.001) in the mean
HO- activity in pancreas (1306.2 ± 182.12 pmol biliru-
bin/mg protein/hr) and liver (1950 ± 287.8 pmol biliru-
bin/mg protein/hr) of diabetic rats compared to the
corresponding control groups (800 ± 184.04 pmol biliru-
bin/mg protein/hr and 1015 ± 213.5 pmol bilirubin/mg
protein/hr), respectively. On the contrary, the HO-
activity in the aorta (343.7 ± 108.35 pmol bilirubin/mgFigure 1 The MDA levels (nmol/g tissue) of studied groups. Values no
presented as mean± SD.protein/hr) of diabetic rats showed a significant decrease
(p < 0.001) compared to the control group (695 ±
180.2 pmol bilirubin/mg protein/hr).
Curcumin derivative supplementation to the control
rats significantly increased (p < 0.001) the HO- activity in
the pancreas (1040 ± 87.55 pmol bilirubin/mg protein/
hr), liver (1545 ± 378.9 pmol bilirubin/mg protein/hr)
and aorta (1025 ± 215.05 pmol bilirubin/mg protein/hr)
compared to the corresponding control groups (800 ±
184.04, 1015 ± 213.5and 695 ± 180.2 pmol bilirubin/mg
protein/hr),respectively.
In addition, curcumin derivative supplementation to
the diabetic rats significantly increased the HO-activity
in the pancreas (1968.7 ± 284.02 pmol bilirubin/mg pro-
tein/hr), liver (2393.7 ± 367.8 pmol bilirubin/mg protein/
hr) and aorta (718 ± 106.69 pmol bilirubin/mg protein/
hr) compared to the corresponding diabetic groups
(1306.2 ± 182.12, 1950 ± 287.8 and 343.7 ± 108.35 pmol
bilirubin/mg protein/hr), respectively.
There was a significant decrease (p < 0.05) in the mean
HO-activity in the diabetic group receiving the oral
NCD combined with HO inhibitor ZnPP in pancreast sharing a common superscript differ significantly (p < 0.05). Results are
Figure 2 HO-1 gene expression (μg/mL) of studied groups. Values not sharing a common superscript differ significantly (p < 0.05). Results are
presented as mean± SD.
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318.15 pmol bilirubin/mg protein/hr) and aorta (415 ±
110.68) compared to the corresponding diabetic group
receiving the oral water soluble curcumin derivative
(1968.7 ± 284.02, 2393.7 ± 367.8 and 718 ± 106.69 pmol
bilirubin/mg protein/hr), respectively (Figure 5).
Lipid profile levels
The mean plasma cholesterol level, LDL cholesterol and
triglycerides levels were significantly higher (p< 0.001)
in the diabetic group (140.1 ± 30.86, 76.4 ± 26.85 and
181.6 ± 25.19 mg/dL, respectively) compared to the
control group (84.4 ± 6.85, 25.4 ± 7.82 and 85.5 ±
7.56 mg/dL, respectively). Also, there was a significant
increase (p< 0.001) in the mean plasma HDL cholesterol
level in the control group (41.8 ± 4.18 mg/dL) compared
to the diabetic group (27.25 ± 4.49 mg/dL).
Curcumin derivative supplementation to diabetic rats
significantly decreased (p < 0.001) the mean plasma chol-
esterol (34.42%), LDL cholesterol (26.5%) and trigly-
cerides (66.64%) levels (91.88 ± 9.61, 25.5 ± 6.76 and
133.5 ± 14.74 mg/dL) compared to the diabetic group
(140.1 ± 30.86, 76.4 ± 26.85 and 181.6 ± 25.19 mg/dL).
On the other hand, it significantly increased (p < 0.001)
the plasma HDL cholesterol level (43.6%) (38.6 ±
4.09 mg/dL) compared to the diabetic group.
No significant difference (p > 0.05) was detected in all
lipid profile levels between the diabetic group receiving
the oral NCD and the diabetic group receiving the oral
water soluble curcumin derivative combined with HO
inhibitor ZnPP (Table 1).
Discussion
To date, most approaches to reduce oxidative stress in
human diabetes have met with little success, and it is nowevident that alternative approaches are required. There are
efforts to search for alternative drugs and herbal medi-
cine that will be a new choice in diabetic treatment.
Of those is curcumin which is a naturally occurring yel-
low pigment powder extracted from the roots of Curcuma
longa. The potential beneficial effects of curcumin have
been shown to exhibit anti-inflammatory [31], antioxi-
dant [32], anti-tumor [33] and anti-diabetic activities [34].
In spite of its efficacy and safety, curcumin has the
major problem of low bioavailability [12]. The present
work evaluates the effect of a novel curcumin derivative
(NCD) developed to overcome the low bioavailability
of curcumin, (PCT/EG2010/000008, Published Patent
Pending, WO 2011/100984). The NCD was designed to
contain the equivalent of only 3.0% curcumin. Induction
of D.M. led to a significant increase of plasma glucose
level and a significant decrease in plasma insulin as
compared to the normal control group. Treatment with
the NCD showed a non-significant decrease in plasma
glucose with a significant increase in plasma insulin in
the control group that receive NCD, as compared to the
normal control group while it significantly lowered the
plasma glucose and increased plasma insulin in the NCD
diabetic group, as compared to the diabetic group.
Several studies proved the effect of curcumin and/or
its derivatives on lowering blood glucose levels in STZ-
induced D.M and in diabetic db/db mice [34, 35]. Rung-
seesantivanon et al., (2010) [36] tested the effect of
curcumin in 30 and 300 mg/Kg body weight doses for
six weeks on STZ-induced diabetic rats. They reported
that both doses of curcumin significantly lowered blood
glucose by 18.73% and 32% respectively, in the diabetic
but not in the control groups. Also Wickenberg et al.,
(2010) [37] reported that the ingestion of 6 g Curcuma
longa increased postprandial serum insulin levels, but
Figure 3 a: Agarose gel electrophoresis showing PCR products
of HO-1and β-actin genes. Lane M: DNA marker (100,200,300
. . .etc.), Lanes 1–4: PCR products of (A) HO-1 gene (316 bp) and (B)
β-actin gene (house keeping gene 202 bp in pancreatic and liver
tissues of studied groups in order: Lane1: Control, Lane2:
Control + NCD, Lane3: Diabetic, Lane4: Diabetic +NCD. b: Agarose
gel electrophoresis showing PCR products of HO-1and β-actin
genes. b: Agarose gel electrophoresis showing PCR products of
HO-1and β-actin genes. Lane M: DNA marker (100,200,300 . . .etc.),
Lanes 1–4: PCR products of (A) HO-1 gene (316 bp) and (B) β-actin
gene (house keeping gene 202 bp in aortic tissues of studied
groups in order: Lane1: Diabetic, Lane2: Control, Lane3:
Diabetic, + NCD, Lane4: Control + NCD.
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The results indicate that Curcuma longa may have an ef-
fect on insulin secretion. They pointed to the fact that in
healthy subjects, glucose levels are strictly regulated, and
it is difficult to measure differences in plasma glucose
levels. This could explain why we did not see any signifi-
cant differences in plasma glucose levels.
EL-Azab et al., (2011) [38] reported that intraperito-
neal injection of curcumin (10 mM. 100μL/mouse) for
28 days showed a significant reduction in blood glucose
in STZ-induced D.M but failed to return to the normal
levels. Curcumin also significantly increased the insulin
level, yet still to a lower extent than the normal levels.
On the other hand, Best et al., (2007) [39], reported
that curcumin induced electrical activity in rat pancreaticβ-cells by activating the volume-regulated anion channel
f, with depolarization of the cell membrane potential, the
generation of electrical activity, and enhanced insulin
release. Another report indicated that curcumin treat-
ment enhances islet recovery by inducing heat-shock
protein Hsp70, a response protein, during cryopreserva-
tion (Kanitkar and Bhonde, 2008) [40] so the activation
of β-cells function by curcumin might contribute to the
hypoglycemic actions of this compound.
This agrees with the results of our previous work on
the effect of curcumin on insulin release in rat isolated
pancreatic islets. We reported that insulin secretion was
significantly increased in islets incubated with curcumin.
Insulin secretion was significantly decreased by incuba-
tion of islets with stannus mesoporphyrin (HO activity
inhibitor), indicating the role of HO-1 in insulin secre-
tion in pancreatic islets [41]. Additionally, curcumin was
found to induce HO-1 expression, which has been
reported to have cytoprotective effects in mouse pancre-
atic β-cells as mediated through the activation of NF-E2-
related factor 2 (Nrf2) and phosphotidylinositol 3-kinase
(PI3-kinase)/Akt-mediated signaling [42].
As for hyperlipidemia it is an associated complication
of D.M. Significant changes in the lipid profile due to in-
duction of D.M. led to, elevations in serum triglycerides,
cholesterol and LDL with a significant decrease in serum
HDL compared to the normal control group. Treatment
with the NCD showed non-significant changes in serum
triglycerides, cholesterol LDL and HDL in the NCD con-
trol group as compared to the normal control group. Re-
spective significant decreases were found in the NCD
diabetic group which gained a significant increase in
HDL as compared to the diabetic group.
Kim and Kim, (2010) [43] reported that curcumin sig-
nificantly decreased serum triglyceride, cholesterol and
LDL and enhanced hepatic cholesterol 7α-hydroxylase
(CYP7A1) gene expression, a rate limiting enzyme in the
biosynthesis of bile acid from cholesterol at the mRNA
level, which may partially account for the role in the
cholesterol lowering effect of curcumin. Accordingly, we
can suggest that curcumin exerts its cholesterol-
lowering actions by modulating cholesterol degradation,
rather than through an antioxidant mechanism.
In D.M. hyperglycemia is thought to induce cell death
through free radical formation [44]. Elevated generation of
free radicals may lead to oxidative damage to cell mem-
brane and enhance lipid peroxidation [45]. The most com-
monly used indicator of lipid peroxidation is MDA [46].
High doses of cell toxins like streptozotocin and alloxan
induce insulin deficiency and type
1 diabetes mellitus with ketosis [47]. Several markers of
vascular inflammation have been shown to be influenced
by the presence of ketosis. It has been reported that
Figure 4 Agarose gel electrophoresis showing PCR products of HO-1and β-actin genes. Lane M: DNA marker (100,200,300 . . .etc.),
Lanes 1–6: PCR products of (A) HO-1 gene (316 bp) and (B) β-actin gene (house keeping gene 202 bp in aortic, pancreatic and liver tissues of
studied groups in order: Lane 1: Diabetic +NCD+ZnPP in aorta, Lane 2: Diabetic +NCD in aorta, Lane 3: Diabetic +NCD+ZnPP in pancreas,
Lane 4: Diabetic +NCD in pancreas, Lane 5: Diabetic +NCD in liver, Lane 6: Diabetic +NCD+ZnPP in liver.
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peroxidation and growth inhibition in cultured human
endothelial cells [48], as well as lowering glutathione
levels in human erythrocytes [49].
In the present study MDA reflected the state of dia-
betic lipid per-oxidation in the pancreas, liver and aorta
as there was significant increase in MDA in the pancreas
as compared to the normal control group. Treatment
with the NCD significantly decreased the levels of MDA
in the pancreas, liver, and aorta. Meanwhile, the same
treatment showed non-significant decrease in MDA
levels in the respective tissues of the NCD control group.
Suryanarayana et al., (2007) [50] reported increased
lipid peroxidation in the liver, kidney, pancreas and heart
of diabetic rats. Previous report [51] showed that curcu-
min increased hepatic reduced glutathione (GSH) and
induced GSH transferase to prevent lipid peroxidation
and detoxify toxic lipid aldehydes in diabetic rats, while
another study [52] showed that curcumin inhibits pro-
tein glycosylation, lipid peroxidation, and oxygen radicalFigure 5 HO- activity (pmol bilirubin/mg protein/hr) of studied group
(p < 0.05). Results are presented as mean± SD.generation in human red blood cells exposed to high
glucose levels.
In the present study paralleled significant increases in
the expression of HO-1 and HO activity due to induc-
tion of D.M. was found in the pancreas and liver with
significant decrease in aorta. Meanwhile, the treatment
has led to a significant increase HO-1 expression in the
NCD control group in the respective tissues with signifi-
cant paralleled increases in HO-activity. Treatment of
the diabetic group led to significant increases in expres-
sion of HO-1 with significant paralleled increases in
HO-activity.
To determine whether curcumin's action is mediated
via inducible HO-1, the HO inhibitor (ZnPP) was admi-
nistered to diabetic rats receiving oral curcumin deriva-
tive. Administration of ZnPP to diabetic rats receiving
curcumin derivative showed a significant increase in the
plasma glucose level and a significant decrease in insulin
levels when compared to the diabetic group and diabetic
group receiving curcumin derivative only. This suggestss. Values not sharing a common superscript differ significantly
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part, mediated through HO-1 induction.
The decrease in HO-1 expression and activity in aortic
tissue in the present work agrees with the work of
Abraham et al., (2004) [53] who reported that the decrease
in HO-1 gene expression and activity in aortic tissues
observed with hyperglycemia in experimental diabetes is
associated with an increase in shedding of endothelial cells
into the circulation, presumably reflecting cell damage.
Although the MDA level was increased in the pan-
creas, liver and aorta of diabetic rats receiving the curcu-
min derivative and ZnPP compared to the diabetic rats
receiving the curcumin derivative only, the increase was
found to be statistically significant (p < 0.05) only in the
aorta . Thus indicating that curcumin decreased the
MDA levels in pancreatic and hepatic tissues by a direct
effect through acting on other antioxidant enzymes
while in aortic tissue this decrease in MDA level might
be through HO-1.
In conclusion
The water soluble curcumin derivative (NCD) by its
small dose with 3.0% curcumin content only has the
ability to decrease plasma glucose and increase plasma
insulin levels significantly in diabetic rats. We find that
antidiabetic actions exerted by NCD may be linked
to heme oxygenase function as a crucial defensive and
detoxifying cellular system, so, heme oxygenase induc-
tion seems to play an important role in its anti-diabetic
effects. NCD appears to improve the lipid profile in dia-
betic rats by lowering total cholesterol, LDL, and trigly-
cerides, while raising HDL levels. It is believed that
curcumin exerts its cholesterol-lowering actions by
modulating cholesterol absorption, degradation, or elim-
ination, rather than through an antioxidant mechanism.
NCD also improves oxidative status, protects and enhances
endogenous defenses directly proved by decreasing lipid
peroxides (malondialdehyde) in pancreas & liver. The
new water soluble curcumin derivative still retains the
essential potencies of natural curcumin.
Recommendations
NCD (given in small doses) provides an opportunity to
expand the clinical range of this efficient herbal agent by
enabling its water solubility. Future studies utilizing
water soluble derivative are recommended to be studied
in humans.
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